The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis

INTRODUCTION: When lenvatinib is administered to people with hepatocellular carcinoma (HCC), tumor blood flow is reduced due to the inhibition of the vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR). Few studies have examined the decrease in tumor bloo...

Descripción completa

Detalles Bibliográficos
Autores principales: Muraishi, Nozomu, Kawamura, Yusuke, Akuta, Norio, Shindoh, Junichi, Matsumura, Masaru, Okubo, Satoshi, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, Hashimoto, Masaji, Yasuda, Ichiro, Kumada, Hiromitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932824/
https://www.ncbi.nlm.nih.gov/pubmed/36103864
http://dx.doi.org/10.1159/000526976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932824/
https://www.ncbi.nlm.nih.gov/pubmed/36103864
http://dx.doi.org/10.1159/000526976

Ejemplares similares